Eli Lilly and Co (NYSE:LLY) announced on Monday that it plans to terminate its clinical trial through which it evaluated a COVID19 antibody treatment as a potential vaccine for the global pandemic.
The biopharma revealed that it decided to abandon the pursuit based on findings from clinical trials. The findings revealed that the antibody vaccine called bamlanivimab does not yield any significant benefits that can improve the health of COVID19 patients. The study's goal and antibody vaccine research was to develop a therapeutic option that would allow COVID19 patients to recover even if they are in advanced stages of the viral infection.
The announcement on the decision to halt the study comes just a few weeks after the company decided to pause its clinical trial due to safety concerns. However, researchers from the National Institutes of Health conducted some investigation and found that the antibody treatment did not present any harm. This finding is also important despite Eli Lilly's decision to discontinue the clinical trials because it can still pursue other uses with the same antibody therapy.
"bamlanivimab is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease," stated.
Eli Lilly to continue investigating bamlaniviman as a potential therapy for early-stage COVID19 infection
Eli Lilly also pointed out in a statement that bamlanivimab still has a lot of potential for use as a monotherapy that can prevent the spread of COVID19 in the early stages of exposure. Together with the National Institutes of Health, the biopharma plans to continue running various trials involving the bamlanivimab antibody therapy. The latter is designed to prevent the virus from infecting healthy cells in the body. The other clinical trials will target patients in the early stages of infections, especially asymptomatic ones.
The clinical trials' goal will be to determine whether the antibody therapy can help boost immunity, allowing the body to combat and clear the virus faster. Eli Lilly is confident that the antibody might yield better results in cases where the body is not already overwhelmed by the virus.